Grove Biopharma
Grove Biopharma is a Chicago-based biopharmaceutical company developing therapeutics that target intracellular protein-protein interactions implicated in cancer, neurodegenerative diseases, and rare disorders. The company pioneered Bionic Biologics, hybrid biomolecules that integrate principles of biologic and synthetic design to achieve cell permeability with customizable, modular construction that can disrupt or degrade disease-causing proteins. Grove has demonstrated proof-of-concept against targets including AR/AR-V7, SHOC2, MYC, TAU, and KEAP1/NRF2. Founded in 2025 and led by CEO Geoffrey Duyk, the company raised a $30M Series A in April 2025 and is backed by DCVC. Grove is a therapeutics company with no public developer API surface; this profile captures its identity for the API Evangelist network.
Grove Biopharma is profiled on the APIs.io network. Tagged areas include Company, Biopharma, Biotechnology, Therapeutics, and Drug Discovery.
Grove Biopharma’s developer surface includes engineering blog and 4 more developer resources.
Kin Score
Resources
Company 5
The organization behind the API